Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 1

Interventions

Decitabine 4Cyclophosphamide 4ruxolitinib 3fludarabine phosphate 3Filgrastim 3Etoposide 3Topotecan 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2LY2784544 2Cytarabine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1umbralisib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1peginterferon alfa-2a 1nelarabine 1navitoclax 1fresolimumab 1durvalumab 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Polycythemia Vera × LY2784544 × Clear all
NCT01134120 2018-04-17

A Study in Myeloproliferative Disorders

Eli Lilly and Company

Phase 1 Completed
80 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01520220 2017-04-12

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Eli Lilly and Company

Phase 1 Completed
100 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡